A proposed combination of Johnson & Johnson’s multiple myeloma bispecific Tecvayli has turned up positive trial data that could put some pressure on CAR T-cell therapies, including the company’s own ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback